CHOOLIP & SCIENCES Inc. (KOSDAQ:291650)
South Korea · Delayed Price · Currency is KRW 1,683.00
-72.00 (-4.10%)
At close: Sep 3, 2026
CHOOLIP & SCIENCES Revenue
In the year 2024, CHOOLIP & SCIENCES had annual revenue of 1.08B KRW with 345.26% growth. CHOOLIP & SCIENCES had revenue of 920.07M in the quarter ending December 31, 2024, with 5,471.58% growth.
Revenue
1.08B
Revenue Growth
+281.58%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
50.51B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.08B | 839.63M | 345.26% |
| Dec 31, 2023 | 243.19M | -115.07M | -32.12% |
| Dec 31, 2022 | 358.25M | 88.98M | 33.04% |
| Dec 31, 2021 | 269.28M | 40.77M | 17.84% |
| Dec 31, 2020 | 228.51M | -179.09M | -43.94% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| KoBioLabs | 75.41B |
| Psomagen | 60.70B |
| J2KBIO | 43.90B |
| PanGen Biotech | 14.18B |
| QuadMedicine | 7.14B |
| TegoScience | 6.18B |
| HLB Pep | 5.54B |
| Parataxis Korea | 1.59B |